RecruitingPhase 2NCT06328049

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

A Prospective, Single-arm, Exploratory Clinical Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

Sponsor

Taixing People's Hospital

Enrollment

30 participants

Start Date

Aug 10, 2023

Study Type

INTERVENTIONAL

Conditions

NSCLC

Summary

The aim of this study is to investigate the safety and efficacy of the prophylactic use of Trilaciclib in patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy, so as to provide more evidence-based medical evidence for the optimal diagnosis and treatment strategy in this population.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether adding a drug called trilaciclib to standard chemotherapy improves outcomes and reduces side effects for people with advanced non-small cell lung cancer (NSCLC) who have not yet had systemic chemotherapy. Trilaciclib works by temporarily protecting the bone marrow during chemotherapy, potentially reducing complications like low blood counts and allowing for more effective treatment. **You may be eligible if...** - You are 18 or older - You have advanced non-small cell lung cancer and have not yet received systemic chemotherapy - Your cancer has not worsened in the 2 weeks before starting study treatment - You are in good health (ECOG 0–1) - Your cancer is measurable on imaging - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have previously received chemotherapy for your lung cancer - You have significant heart conditions - You are pregnant or breastfeeding (contraception required) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTrilaciclib Injection

Patients with lung adenocarcinoma were given Trilaciclib combined with pemetrexed and carboplatin, Q3W; For patients with lung squamous cell carcinoma,Trilaciclib combined with paclitaxel/albumin-bound paclitaxel and carboplatin, Q3W. From cycle 2 onwards, patients chose whether to use trasylol with chemotherapy.

Locations(1)

Taixing People's Hospital

Taishing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06328049

Related Trials

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

NCT056578739 locations

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143207 locations

Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

NCT075591231 location

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NCT0634340235 locations

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

NCT064316851 location